These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 25394622)
1. Cost effectiveness has its place, but so does common sense. Rappuoli R; Wassil J; Bonefeld L; Porter J BMJ; 2014 Nov; 349():g6759. PubMed ID: 25394622 [No Abstract] [Full Text] [Related]
2. Potential long term vaccine benefits poorly translate in cost effectiveness modelling. Black S BMJ; 2014 Nov; 349():g6764. PubMed ID: 25394571 [No Abstract] [Full Text] [Related]
3. Winter is coming: vaccine negotiations should be concluded swiftly. Glennie L; Wright C; Head C BMJ; 2014 Nov; 349():g6748. PubMed ID: 25394501 [No Abstract] [Full Text] [Related]
4. Authors' reply to Rappuoli and colleagues, Black, and Glennie and colleagues. Christensen H; Trotter CL; Hickman M; Edmunds WJ BMJ; 2014 Nov; 349():g6758. PubMed ID: 25394639 [No Abstract] [Full Text] [Related]
5. Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis. Miller MA; Shahab CK Pharmacoeconomics; 2005; 23(4):333-43. PubMed ID: 15853434 [TBL] [Abstract][Full Text] [Related]
7. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE; Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206 [TBL] [Abstract][Full Text] [Related]
8. Is there a need for a public vaccine production capacity at European level? Levy-Bruhl D Euro Surveill; 2006 Jul; 11(7):148-9. PubMed ID: 16966801 [No Abstract] [Full Text] [Related]
10. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad. Lydon P; Zipursky S; Tevi-Benissan C; Djingarey MH; Gbedonou P; Youssouf BO; Zaffran M Bull World Health Organ; 2014 Feb; 92(2):86-92. PubMed ID: 24623901 [TBL] [Abstract][Full Text] [Related]
11. Neisseria meningitidis serogroup A vaccines: an overview. Vergnano S; Heath P Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341 [TBL] [Abstract][Full Text] [Related]
14. Vaccine introduction. The beginning of the end for Africa's devastating meningitis outbreaks? Roberts L Science; 2010 Dec; 330(6010):1466-7. PubMed ID: 21148362 [No Abstract] [Full Text] [Related]
15. [Africa: towards the eradication of meningitis A?]. Nau JY Rev Med Suisse; 2011 Jun; 7(300):1378-9. PubMed ID: 21815540 [No Abstract] [Full Text] [Related]
16. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines. Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678 [TBL] [Abstract][Full Text] [Related]
17. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations]. Gendrel D Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370 [TBL] [Abstract][Full Text] [Related]
18. Is public meningococcal C vaccination the preferred value for money at cost-neutral? Gravatt L N Z Med J; 2013 Oct; 126(1384):123-5. PubMed ID: 24162638 [No Abstract] [Full Text] [Related]
19. Meningitis B. The Lancet Lancet; 2013 Aug; 382(9890):368. PubMed ID: 23911364 [No Abstract] [Full Text] [Related]
20. Immunisation against meningococcus B. Head C Lancet; 2013 Sep; 382(9896):935. PubMed ID: 24034290 [No Abstract] [Full Text] [Related] [Next] [New Search]